Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management

Hematology/Oncology Clinics of North America

Volumn 22, Issue 1, 2008, Pages 155-174

  Baker Jr , William F ^a,b,c   Bick, Rodger L ^d   Fareed, Jawed ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Clinical Thrombosis Center   (United States)

^c KERN MEDICAL CENTER   (United States)

^d Loyola University Chicago ^*  (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN; CELL ADHESION MOLECULE; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFIBROTIDE; FIBRINOLYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PROCOAGULANT; PROSTACYCLIN; PROTEIN C; PROTEIN S; RITUXIMAB; THROMBOMODULIN; WARFARIN;

ADD ON THERAPY; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTERY THROMBOSIS; CLINICAL FEATURE; CYTOTROPHOBLAST; DECISION MAKING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC PREDISPOSITION; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MOLECULAR MIMICRY; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; STROKE; TERMINAL DISEASE; THROMBOCYTE ACTIVATION; THROMBOSIS; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CATASTROPHIC ILLNESS; FIBRINOLYTIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; THROMBOSIS;

EID: 38349000903     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.10.006     Document Type: Review

References (87)

1. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 10 (2002) 752-763
2. Haserick J., and Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphillis: presentation of five cases. Ann Intern Med 37 (1952) 559-565
3. Moore J., and Mohr C. Biologically false positive tests for syphillis: type, incidence, and cause. JAMA 150 (1952) 467
4. Rand J.H. The antiphospholipid syndrome. In: Beutler E. (Ed). Williams hematology. 6th edition (2001), McGraw-Hill, New York 1715-1733
5. Conley C., and Hartmann R. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythemasosus. J Clin Invest 31 (1952) 621
6. Bowie W., Thompson J., Pascuzzi C., et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Clin Invest 62 (1963) 416
7. Harris E.N., Gharavi A., Boey M., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2 (1983) 1211-1214
8. Hughes G. The anticardiolipin syndrome. Clin Exp Rheumatol 3 (1985) 285
9. Galli M., Comfurius P., Barbui T., et al. Anticoagulant activity of B2-glycoprotein-I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68 (1992) 297-300
10. McNeil H., Simpson R., Chesterman C., et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: B2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87 (1990) 4120-4124
11. Hunt J., McNeil H., Morgan G., et al. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1 (1992) 75-81
12. Arvieux J., Roussel B., Jacob M.C., et al. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 143 (1991) 223-229
13. Hanly J., and Smith S. Anti-beta2-glycoprotein I (GPI) autoantibodies annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 120 (2000) 537
14. Bick R., and Baker W. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 25 (1999) 333-350
15. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev 6 2 (2006) 76-80
16. Miret C., Cervera R., Reverter J.C., et al. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient "seronegative" antiphospholipid syndrome?. Clin Exp Rheumatol 15 (1997) 541
17. Arnout J., and Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 1 (2003) 931
18. Gharavi A., Pierangeli S., and Harris E.N. Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 27 (2001) 551
19. Rauch J., Subang R., D'Agnillo P., et al. Apoptosis and the antiphospholipid syndrome. J Autoimmun 15 (2000) 231
20. Horkko S., Miller E., Dudl E., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98 (1996) 815
21. Walenga J., Michal K., Hoppensteadt D., et al. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 5 Suppl 1 (1999) S76
22. Hellan M., Kuhnel E., Speiser W., et al. Familial lupus anticoagulant: a case report and review of the literature. Blood Coagul Fibrinolysis 9 (1998) 195
23. Pierangeli S., Gharavi A., and Harris E.N. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun 15 (2000) 241
24. Takeuchi R., Atsumi T., Ieko M., et al. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 119 (2002) 781
25. Tsakiris D.A., Settas L., PM, et al. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 17 (1990) 785
26. Koike T., Bohgaki M., Amengual O., et al. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28 2-3 (2007) 129-133
27. Di Simone N., Castellani R., Caliandro D., et al. Antiphospholipid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 77 (2002) 805
28. Ozturk M.A., Haznedaroglu I.C., Turgut M., et al. Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clin Appl Thromb Hemost 10 2 (2004) 89-126
29. Wilson W., Gharavi A., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
30. Galli M., Borrelli G., Jacobsen E.M., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (Warfarin in the Anti-Phospholipid Syndrome) study. Blood 110 4 (2007) 1178-1185
31. Carreras L.O., Forastiero R.R., and Martinuzzo M. Which are the best biological markers of the antiphospholipid syndrome?. J Autoimmun 15 (2000) 163
32. Bick R. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 17 (2003) 115
33. Khamashta M., Cuadrado M., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
34. Moll S., and Ortel T. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127 (1997) 177-185
35. Baker R.I. Prevention of recurrent thrombosis in the antiphospholipid antibody syndrome: how long and how high with oral anticoagulant therapy?. Med J Aust 180 9 (2004) 436-437
36. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systemic review and meta-analysis. Arch Intern Med 167 15 (2007) 1593-1599
37. Kitchens C. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104 (1998) 381-385
38. Rand J.H. Molecluar pathogenesis of the antiphospholipid syndrome. Circ Res 90 (2002) 29
39. Gharavi A.E., Wilson W., and Pierangeli S. The molecular basis of antiphospholipid syndrome. Lupus 12 8 (2003) 579-583
40. Rahgozar S., Yang Q., Giannakopoulos B., et al. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 56 2 (2007) 605-613
41. Mackworth-Young C.G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 136 3 (2004) 393-401
42. Schousboe I. B2-Glycoprotein I: a plasma inhibitor of the contact activation of the blood coagulation pathway. Blood 66 (1985) 1086-1091
43. Nimpf J., Bevers E., Bomans P., et al. Prothrombinase activity of human platelets is inhibited by beta2-glycoprotein-I. Biochim Biophys Acta 884 (1986) 142
44. Nimpf J., Wurm H., and Kostner G. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63 (1987) 109
45. Henry M., Everson B., and Ratnoff D. Inhibition of the activation of Hageman factor (factor XII) by beta2-glycoprotein I. J Lab Clin Med 111 (1988) 519
46. Merrill J., Zhang H., Shen C., et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 81 (1999) 748
47. Ieko M., Yasokouchi T., Sawada K., et al. The influence of beta2-glycoprotein I on tissue factor activity. Semin Thromb Hemost 24 (1998) 211
48. Bancsi L., van der Linden I., and Bertina R. Beta 2 glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 67 (1992) 649
49. Rosove M., and Brewer P. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
50. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
51. Abuaf N., Meyer O., Laperche S., et al. Conclusions of the first French workshop of standardization of anticardiolipin antibody determination associated with autoimmune pathology. Ann Biol Clin (Paris) 52 (1994) 365
52. Favaloro E., and Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 118 (2002) 548
53. Gerbutavicus R., Fareed J., Messmore H., et al. Reference ranges of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom titer tests revisited. Clin Appl Thromb Hemost 8 (2002) 51
54. Ruiz-Irastorza G., Egurbide M.V., Ugalde J., et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 164 1 (2004) 77-82
55. Brandt J., Triplett D.A., Alving B., et al. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74 (1995) 1185-1190
56. Wasmuth J., Minarro D., Homrighausen A., et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin Chem 48 (2002) 1004
57. Passam F., and Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 36 2 (2004) 129-138
58. Silver R.M., Pierangeli S., Edwin S.S., et al. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Obstet Gynecol 176 (1997) 628
59. Galli M., Luciani D., Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827
60. Diri E., Cucurull E., Gharavi A., et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 8 (1999) 263
61. Bertolaccini M.L., Atsumi T., Escudero Contreras A., et al. The value of IgA antiphospholipid testing for diagnosis of the antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 28 (2001) 2637
62. Selva O., Ordi R., Monegal F., et al. Anticardiolipin antibodies-relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 79 (1998) 282
63. Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?. J Autoimmun 15 (2000) 101
64. Nojima J., Kuratsune H., Suehisa E., et al. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 114 (2001) 647
65. Lakos G., Kiss E., Regeczy N., et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune disease. J Rheumatol 27 (2000) 924
66. Forastiero R.R., Martinuzzo M., Cerrato G., et al. Relationship of anti beta2-glycoprotein I and anti-prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 78 (1997) 1008
67. Kaburaki J., Kuwana M., Yamamato M., et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 54 (1997) 209
68. Ogawa H., Zhao D., Dlott J., et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 114 (2000) 619
69. Branch D.W., Rote N., Dostal D., et al. Association of lupus anticoagulant with antibody against phosphatidylserine. Clin Immunol Immunopathol 42 (1987) 63
70. Berard M., Chantome R., Marcelli A., et al. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. [see comments]. J Rheumatol 23 (1996) 1369
71. Laroche P., Berard M., Rouquette A., et al. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 106 (1996) 549
72. Branch D.W., Silver R.M., Pierangeli S., et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls and antiphospholipid syndrome. Obstet Gynecol 89 (1997) 549
73. Ho Y., Chen M., Wu C., et al. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid syndrome. Cardiology 87 (1996) 354
74. Jankowski M., Dudek D., Dubiel J., et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 9 (1998) 753
75. Derksen R., and de Groot P. Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation?. J Autoimmun 15 (2000) 255
76. Wardlaw J., del Zoppo G., Yamaguchi T., et al. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev 2 (2000) CD 000213
77. Gatenby P.A. Controversies in the antiphospholipid syndrome and stroke. Thromb Res 114 5-6 (2004) 483-488
78. Committee TAW. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischaemic stroke. JAMA 291 (2004) 576-584
79. Pullicino P., Mohr J., Thompson J., et al. ftW-ARSSG. A comparison of warfarin and aspirin for the prevention of recurrent ischaemic stroke. N Engl J Med 345 (2001) 1444-1451
80. Group TEASPiRITES. Oral anticoagulation in patients after cerebral ischaemia of arterial origin and risk of intracranial hemorrhage. Stroke 34 (2003) 45-47
81. Haas S. Treatment of deep venous thrombosis and pulmonary embolism: current recommendations. Med Clin North Am 82 (1998) 495-510
82. Derksen R., de Groot P., Kater L., et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52 (1993) 689-692
83. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 12 (2003) 1133-1138
84. Fefer P., Hod H., and Matetzky S. Clopidogrel resistance-the cardiologist's perspective. Platelets 18 3 (2007) 175-181
85. Bick R. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 6 (2000) 115
86. Asherson R.A. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
87. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6 (2006) 98-103